Insider · CIK 0001619929

NABEL ELIZABETH G

Reports to the SEC for 9 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001619929

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-10	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+9,250 sh	—	—	9,250
2026-05-06	MRNAModerna, Inc. · Restricted Stock UnitsA Award	Director	AAward	+8,371 sh	—	—	8,371
2026-04-30	MRNAModerna, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+16.2K sh	—	—	19,317
2026-04-30	MRNAModerna, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−16.2K sh	—	—	0
2026-04-28	MDTMedtronic plcF Tax Payment	Director	FTax Payment	−207 sh	$81.90	−$17K	19,584
2026-04-27	MDTMedtronic plcA Award	Director	AAward	+2,111 sh	—	—	19,791
2025-05-15	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+130K sh	—	—	130,000
2025-04-30	MRNAModerna, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+979 sh	—	—	3,084
2025-04-30	MRNAModerna, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−979 sh	—	—	0
2025-04-30	MRNAModerna, Inc. · Restricted Stock UnitsA Award	Director	AAward	+16.2K sh	—	—	16,233
2025-04-29	MDTMedtronic plcF Tax Payment	Director	FTax Payment	−216 sh	$84.60	−$18.3K	17,615
2025-04-28	MDTMedtronic plcA Award	Director	AAward	+2,083 sh	$84.04	+$175K	17,831
2025-04-08	Accolade, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−42K sh	$7.03	−$295K	0
2025-04-08	Accolade, Inc.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−35K sh	—	—	0
2025-04-08	Accolade, Inc.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−12.5K sh	—	—	0
2025-03-03	Accolade, Inc.Restricted Stock UnitsA Award	Director	AAward	+12.5K sh	—	—	12,489
2025-02-28	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,178 sh	—	—	41,982
2025-02-28	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−2,178 sh	—	—	0
2024-12-02	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,179 sh	—	—	39,804
2024-12-02	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−2,179 sh	—	—	2,178
2024-09-03	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,179 sh	—	—	37,625
2024-09-03	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−2,179 sh	—	—	4,357
2024-08-06	Accolade, Inc.Restricted Stock UnitsA Award	Director	AAward	+35K sh	—	—	35,021
2024-08-06	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,196 sh	—	—	35,446
2024-08-06	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,196 sh	—	—	0
2024-06-14	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+130K sh	—	—	130,000
2024-05-31	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,179 sh	—	—	26,250
2024-05-31	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−2,179 sh	—	—	6,536
2024-05-06	MRNAModerna, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,668 sh	—	—	5,668
2024-05-06	MRNAModerna, Inc. · Restricted Stock UnitsA Award	Director	AAward	+979 sh	—	—	979
2024-05-03	MRNAModerna, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+732 sh	—	—	2,105
2024-05-03	MRNAModerna, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−732 sh	—	—	0
2024-05-01	MDTMedtronic plcF Tax Payment	Director	FTax Payment	−192 sh	$80.89	−$15.5K	15,674
2024-04-29	MDTMedtronic plcA Award	Director	AAward	+2,165 sh	$80.86	+$175K	15,866
2024-03-01	Accolade, Inc.Restricted Stock UnitsA Award	Director	AAward	+8,715 sh	—	—	8,715
2024-02-29	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,751 sh	—	—	24,071
2024-02-29	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−1,751 sh	—	—	0
2023-11-30	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,751 sh	—	—	22,320
2023-11-30	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−1,751 sh	—	—	1,751
2023-09-08	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+55K sh	—	—	55,000
2023-08-31	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,752 sh	—	—	20,569
2023-08-31	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−1,752 sh	—	—	3,502
2023-08-18	Accolade, Inc.Restricted Stock UnitsA Award	Director	AAward	+9,196 sh	—	—	9,196
2023-07-25	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+14.1K sh	—	—	18,817
2023-07-25	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−14.1K sh	—	—	0
2023-06-16	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Director	AAward	+65K sh	—	—	65,000
2023-05-31	Accolade, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,752 sh	—	—	4,757
2023-05-31	Accolade, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−1,752 sh	—	—	5,254
2023-05-03	MRNAModerna, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+4,601 sh	—	—	4,601
2023-05-03	MRNAModerna, Inc. · Restricted Stock UnitsA Award	Director	AAward	+732 sh	—	—	732

Recent filings

Accepted (ET)
Jun 124
NABEL ELIZABETH G0001619929-26-000004
SEC(opens sec.gov)
May 84
NABEL ELIZABETH G0001682852-26-000091
SEC(opens sec.gov)
May 44
NABEL ELIZABETH G0001682852-26-000066
SEC(opens sec.gov)
Apr 294
NABEL ELIZABETH G0001619929-26-000002
SEC(opens sec.gov)
May 194
NABEL ELIZABETH G0001415889-25-013707
SEC(opens sec.gov)
May 14
NABEL ELIZABETH G0001127602-25-012938
SEC(opens sec.gov)
Apr 304
NABEL ELIZABETH G0001613103-25-000069
SEC(opens sec.gov)
Apr 84
NABEL ELIZABETH G0001415889-25-010340
SEC(opens sec.gov)
Mar 54
NABEL ELIZABETH G0001127602-25-008236
SEC(opens sec.gov)
Mar 44
NABEL ELIZABETH G0001127602-25-007668
SEC(opens sec.gov)
Dec 44
NABEL ELIZABETH G0001127602-24-028585
SEC(opens sec.gov)

Companies

Address

C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY, SUITE 101

SOUTH SAN FRANCISCO, CA, 94080